RESPIRATORY FUNCTION IN PATIENTS WITH HIV POSTINFECTION BY COVID-19

ABSTRACT

SESSION TITLE Post-COVID-19 Outcomes SESSION TYPE Rapid Fire Original Inv PRESENTED ON 10/19/2022 1115 am - 1215 pm PURPOSE: Alterations in lung function may occur in patients with HIV and who were infected with SARSCoV2. In order to describe this characteristics we created the following groups Group (1) HIV (+) SARS-COV-2 (+), Group (2) HIV (+) SARS-COV-2 (-), Group (3) HIV (-) SARS-COV2 (+), Group (4) HIV (-) SARS-COV-2 (-). METHODS: In this prospective, longitudinal cohort we included patients with infection with SARS-CoV-2 ( RT- PCR test o Antigen Testing positive) who agreed to participate in the study. Spirometry, diffusing capacity of carbon monoxide (DLCO), body plethysmography, and 6-minute walk test (6MWT) were performed to assess lung function 3 to 6 months after SARS-CoV2 infection, clinical and laboratory characteristics were assesed. We performed descriptive statistics including means and standar deviations for normally distributed continous variables, medians and interquartile ranges for non-parametric distributions, and proportions for categorical variables. The comparisons between groups were made using Fisher´s exact test and Mann-Whitney U for categorical and continous variables respectively. RESULTS: During the between April 2021-February 2022, a total of 104 patients were included. Group (1)44 patients (14 were hospitalized), Group (2)19 patients, Group (3)26 patients (16 were hospitalized), Group (4)15 patients. Hypertension was higher in the Group HIV (-) SARS-COV-2 (+). We didn´t find differences in lung pulmonary function (Spirometry, DLCO, body plethysmography or 6MWT between groups). Spirometry results: FEV1/FVC % Predicted Group 1 58.0 [25.5, 74.0], Group 242.5 [19.5, 65.5], Group 3 55.0 [38.5, 80.5], Group 4 35.0 [19.0, 68.5], HIV(+)/HIV(-) p-value 0.43. DLCO% predicted Group 1 82.7 [71.5, 90.0], Group 2 86.7 [76.8, 96.3], Group 3 85.6 [76.8, 91.6], Group 4 88.3 [85.7, 98.6], p 0.199. Total lung capacity (TLC) % of predicted, Group 1 101 [88.8, 109], Group 2 99.5 [97.0, 112], Group 3 102 [94.3, 112], Group 4 111 [103, 115], p 0.105. 6MWT Group 1 566 [529, 604], Group 2 595 [548, 622], Group 3 548 [493, 604], Group 4 593 [547, 630], p 0.702. CONCLUSIONS: To our knowledge, this is the first study to characterize pulmonary function in ill COVID-19 survivors with HIV. Our results suggest not difference between the lung function tests performed in patients coinfected with HIV and SARS-CoV 2 compared to patients infected with SARS-CoV2 HIV (-). Limitations, not pre-testing pulmonary function. Inclusion of a greater number of HIV (-) patients who required hospitalization. CLINICAL IMPLICATIONS Beyond the effects of SARS-CoV2 on HIV outcomes, it is essential to examine whether HIV has an impact on susceptibility to COVID-19 or if it will generate changes that lead to increased sequelae in these patients. It is well known that patients with HIV may be at increased risk of lung function test abnormalities due to the infection itself, as well as some additional exposures. DISCLOSURES No relevant relationships by Olivia Briceño No relevant relationships by GUSTAVO CASAS no disclosure on file for Mauricio Gonzalez Navarro;No relevant relationships by Alejandro Juárez Díaz No relevant relationships by William C. Lara-Vazquez No relevant relationships by María Isabel León Rodríguez No relevant relationships by JOSE CHRISTIAN RODRIGUEZ HERNANDEZ No relevant relationships by Gonzalo Salgado